Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma.
Saved in:
| Title: | Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. |
|---|---|
| Authors: | Bakouny Z; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Braun DA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Shukla SA; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA., Pan W; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Gao X; Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA, USA., Hou Y; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA., Flaifel A; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Tang S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Bosma-Moody A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., He MX; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Vokes N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Nyman J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Xie W; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA., Nassar AH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Abou Alaiwi S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Flippot R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Bouchard G; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Steinharter JA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Nuzzo PV; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Ficial M; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Sant'Angelo M; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Forman J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Berchuck JE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Dudani S; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada., Bi K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Park J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Camp S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Sticco-Ivins M; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Hirsch L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Baca SC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Wind-Rotolo M; Bristol-Myers Squibb, Princeton, NJ, USA., Ross-Macdonald P; Bristol-Myers Squibb, Princeton, NJ, USA., Sun M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Lee GM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Chang SL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Wei XX; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., McGregor BA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Harshman LC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Genovese G; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ellis L; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA., Pomerantz M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Hirsch MS; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Freedman ML; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Atkins MB; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA., Wu CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Ho TH; Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, USA., Linehan WM; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA., McDermott DF; Beth Israel Deaconess Medical Center, Boston, MA, USA., Heng DYC; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada., Viswanathan SR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Signoretti S; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA., Van Allen EM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. eliezerm_vanallen@dfci.harvard.edu., Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Toni_Choueiri@dfci.harvard.edu. |
| Source: | Nature communications [Nat Commun] 2021 Feb 05; Vol. 12 (1), pp. 808. Date of Electronic Publication: 2021 Feb 05. |
| Publication Type: | Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-021-21068-9 |
